Treatment of falciparum malaria from Vietnam with a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090).
Two new investigational antimalarial drugs developed by the U.S. Army Malaria Research Program were tested in patients with multi-drug-resistant falciparum malaria from Vietnam. WR 33063, a phenanthrene methanol, cured 13 patients treated in the United States. All of these patients had suffered multiple recrudescences after treatment with standard antimalarial drugs. In addition, 23 of 25 patients with acute attacks of falciparum malaria treated in Vietnam were cured. The rate of clinical response was prompt. WR 30090, a quinoline methanol, similarly cured eight patients with multiple recrudescences in the United States and 23 of 26 patients in Vietnam. Adverse effects associated with the drugs were not seen. These drugs signify a major advance in the chemotherapy of drug-resistant falciparum malaria.
D000962:Antimalarials / Q000627:therapeutic use*; D002082:Butylamines / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D000432:Methanol / Q000627:therapeutic use; D008744:Methylamines / Q000627:therapeutic use; D010616:Phenanthrenes / Q000627:therapeutic use*; D010963:Plasmodium falciparum; D011804:Quinolines / Q000627:therapeutic use*; D014744:Vietnam
D000962:Antimalarials; D002082:Butylamines; D008744:Methylamines; D010616:Phenanthrenes; D011804:Quinolines; D000432:Methanol